Drug Trial Radar · NCT07322887
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
May 1, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.Industry
- Sponsor type
- Industry
- Collaborators
- Sulfateq B.V.
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan. It will also learn about the safety of new drug SUL-238. The main questions it aims to answer are: * Does new drug SUL-238 improve the mitochondrial function in patients with Parkinson's Disease (PD)? * What medical problems do participants have when taking new drug SUL-238? Researchers will compare new drug SUL-238 to a placebo (a look-alike substance that contains no drug) to see if SUL-238 works to improve mitochondrial function in patients with PD. Participants will: * Take new drug SUL-238 or a placebo every day for 28 days * Visit the clinic once every 2 weeks for checkups and tests during the treatment period and finally 28 days after the last dose of SUL-238 * Keep a diary of their symptoms and the number of times they use oral new drug SUL-238
Conditions
- Parkinson's Disease (PD)
Interventions
SUL-238 (1500 mg t.i.d.) film-coated tabletsDrug
Oral treatment with high dose SUL-238 for 28 days
SUL-238 (500 mg t.i.d.) film-coated tabletsDrug
Oral treatment with low dose SUL-238 for 28 days
PlaceboDrug
Oral treatment with placebo for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the effect of SUL-238 on mitochondria-related brain metabolites in Parkinson's Disease (PD) PatientsTime frame: At baseline and end of treatment at 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CTC Netherlands BV
Groningen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.